Research programme: inflammatory disorder therapeutics - Teva

Drug Profile

Research programme: inflammatory disorder therapeutics - Teva

Alternative Names: ART123; CEP-37248

Latest Information Update: 20 Feb 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Arana Therapeutics
  • Developer Cephalon
  • Class Antibodies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 17 Feb 2010 Preclinical development is ongoing with Cephalon in the US
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 01 Oct 2008 Preclinical trials in Inflammation in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top